The dual Syk/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

PURPOSE: B-cell receptor (BCR)-associated kinase inhibitors such as ibrutinib have revolutionised the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative and resistance is already emerging in a proportion of patients. Interleukin-4 (IL-4), expressed in CLL lymph n...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Blunt, Matthew D, Koehrer, Stefan, Dobson, Rachel, Larrayoz, Marta, Wilmore, Sarah, Hayman, Alice, Parnell, Jack, Smith, Lindsay, Davies, Andrew, Johnson, Peter W, Conley, Pamela B, Pandey, Anjali, Strefford, Jon C, Stevenson, Freda K, Packham, Graham, Forconi, Francesco, Coffey, Greg, Burger, Jan A, Steele, Andrew J
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5417366/
https://ncbi.nlm.nih.gov/pubmed/27697994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1662
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki